Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts

Autor: James B. Parkerson, Julie A.A. Borland, Magdi H. Yacoub, Adrian H. Chester, John D. Catravas, Simon Crabbe
Rok vydání: 1998
Předmět:
Adult
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Captopril
Pyridines
medicine.drug_class
Angiotensin-Converting Enzyme Inhibitors
Internal thoracic artery
In Vitro Techniques
Peptidyl-Dipeptidase A
Receptor
Angiotensin
Type 2
Losartan
Receptor
Angiotensin
Type 1
Angiotensin Receptor Antagonists
Thoracic Arteries
Internal medicine
medicine.artery
Humans
Vasoconstrictor Agents
Medicine
Saphenous Vein
Coronary Artery Bypass
Aged
Receptors
Angiotensin
biology
business.industry
Endothelin receptor antagonist
Angiotensin II
Graft Occlusion
Vascular
Imidazoles
Angiotensin-converting enzyme
Middle Aged
Receptor antagonist
Endocrinology
Vasoconstriction
cardiovascular system
biology.protein
Female
Surgery
Nitric Oxide Synthase
Cardiology and Cardiovascular Medicine
business
Vein graft disease
medicine.drug
Zdroj: The Journal of Thoracic and Cardiovascular Surgery. 116:206-212
ISSN: 0022-5223
DOI: 10.1016/s0022-5223(98)70118-7
Popis: Objective: The activity of the renin-angiotensin system may be important in determining the performance of coronary artery bypass grafts. We have examined the activity of tissue angiotensin-converting enzyme and the effects of angiotensin II in vessels used as bypass grafts. Methods: Organ bath studies were used to determine the vasoactive effect of angiotensin II. The activity of the angiotensin-converting enzyme was assessed by metabolism of a specific synthetic substrate. Results: The saphenous vein produced greater maximum responses to angiotensin II than did the internal thoracic artery. This response was not modified by inhibition of nitric oxide synthase, cyclooxygenase, or by an endothelin receptor antagonist in either vessel. Losartan, an AT 1 receptor antagonist, inhibited the vasoconstrictor response in both blood vessels. Homogenates of saphenous vein and internal thoracic artery displayed tissue angiotensin-converting enzyme activity, which was inhibited by captopril. Enzyme activity was threefold greater in the vein. Both the contractile response to angiotensin II and the enzyme activity were retained in venous grafts removed up to 20 years after coronary bypass surgery. Conclusions: These data demonstrate that marked differences exist in angiotensin-converting enzyme activity and AT 1 receptor responses in the saphenous vein compared with the internal thoracic artery. These findings may have important implications for the performance of the vein when used as a coronary artery bypass graft and may have clinical implications for the use of angiotensin-converting inhibitors and AT 1 receptor antagonists in the prevention and treatment of vein graft disease. (J Thorac Cardiovasc Surg 1998;116:206-12)
Databáze: OpenAIRE
Externí odkaz: